LORYNA
Clinical safety rating: caution
Comprehensive clinical and safety monograph for LORYNA (LORYNA).
Selective mineralocorticoid receptor antagonist, blocking aldosterone binding to the mineralocorticoid receptor in epithelial and nonepithelial tissues.
| Metabolism | Hepatic via CYP3A4 |
| Excretion | Primarily excreted via feces (80%) after biliary elimination; renal excretion accounts for approximately 10% as unchanged drug and metabolites. |
| Half-life | Terminal elimination half-life is 18–24 hours in healthy adults; may be prolonged in severe hepatic impairment. |
| Protein binding | High protein binding (>99%) mainly to albumin and alpha-1-acid glycoprotein. |
| Volume of Distribution | Volume of distribution is 0.4–0.6 L/kg, indicating distribution into total body water and some tissue binding. |
| Bioavailability | Oral bioavailability is approximately 50–60% due to extensive first-pass metabolism. |
| Onset of Action | Oral: 30–60 minutes for clinical effect. |
| Duration of Action | Duration of action is 8–12 hours after single dose; sustained effects with repeated dosing due to long half-life. |
5 mg orally once daily, with or without food. Maximum dose 10 mg once daily.
| Dosage form | TABLET |
| Renal impairment | GFR 30-89 mL/min: No adjustment. GFR 15-29 mL/min: 2.5 mg once daily. GFR <15 mL/min or dialysis: Not recommended. |
| Liver impairment | Child-Pugh A: No adjustment. Child-Pugh B: 2.5 mg once daily. Child-Pugh C: Not recommended. |
| Pediatric use | Not established for patients under 18 years. |
| Geriatric use | Start at 2.5 mg once daily due to increased sensitivity; titrate based on response and tolerability. |
| 1st trimester | Consult provider |
| 2nd trimester | Consult provider |
| 3rd trimester | Consult provider |
Clinical note
Comprehensive clinical and safety monograph for LORYNA (LORYNA).
| Breastfeeding | Topiramate is excreted into breast milk with a milk-to-plasma (M/P) ratio of approximately 0.66. Infant serum levels can reach 10-20% of maternal therapeutic levels. Caution advised due to potential adverse effects (e.g., drowsiness, diarrhea, poor feeding). Use only if benefit outweighs risk. |
| Teratogenic Risk | First trimester: Increased risk of neural tube defects (anencephaly, spina bifida) and cardiovascular anomalies based on human data from antiepileptic drugs similar to topiramate. Second/third trimester: Risk of fetal growth restriction, low birth weight, and possibly preterm delivery. Overall, topiramate is considered teratogenic (Pregnancy Category D). |
■ FDA Black Box Warning
None
| Serious Effects |
["Serum potassium >5.5 mEq/L at initiation","Moderate to severe renal impairment (CrCl <30 mL/min)","Concomitant use with strong CYP3A4 inhibitors"]
| Precautions | ["Hyperkalemia","Renal impairment","Additive effect with other potassium-sparing diuretics or ACE inhibitors/ARBs"] |
Loading safety data…
| Fetal Monitoring | Maternal: Baseline and periodic serum topiramate levels, renal function, electrolytes, and liver function. Monitor for metabolic acidosis, glaucoma, and cognitive side effects. Fetal: Detailed ultrasound for structural anomalies in first trimester, growth scans in second/third trimesters. Consider amniocentesis if indicated. |
| Fertility Effects | In women, topiramate may cause reversible menstrual irregularities and anovulation, potentially reducing fertility. In men, no significant impact on spermatogenesis reported. Caution in women planning pregnancy due to teratogenicity. |